Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women by Kim, Seung Cheol et al.
Objective: The study assessed the immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical 
cancer vaccine in healthy Korean women aged 15-25 years.
Methods: Phase IIIB, double-blind, randomised (2:1), multi-centre trial was conducted in Korea from June 2007 to March 2008. 
The study enrolled 225 women in the HPV (N=149) and placebo (N=76) groups who received three doses of HPV-16/18 AS04-adju-
vanted vaccine or placebo (aluminium hydroxide) administered intramuscularly at 0, 1, and 6 months and were followed until 
one month post-dose 3. Serum samples were collected pre-vaccination and one month post-dose 3. Safety and reactogenicity 
data were collected throughout.
Results: In this trial, 208 women completed the study (141 in HPV group; 67 in placebo group). At month 7, all initially seronega-
tive women had seroconverted for HPV-16 and HPV-18 antibodies with anti-HPV-16 and anti-HPV-18 geometric mean titres of 
9,351.4 El.U/mL (95% CI, 8,145.5 to 10,735.8) and 4204.1 El.U/mL (95% CI, 3,626.5 to 4,873.6), respectively. Initially seropositive 
women showed similar increase in geometric mean titre levels. Compliance to the three dose vaccination course was 95.3% in 
HPV and 89.5% in placebo group. Solicited local (pain) and general (fatigue, myalgia or headache) symptoms were commonly 
reported in both groups. Three serious adverse events were reported (two in HPV group; one in placebo group), all unrelated to 
vaccination by the investigator; all recovered.
Conclusion: The HPV-16/18 AS04-adjuvanted vaccine was highly immunogenic with a clinically acceptable safety profile in Korean 
women. This study was in line with previous global studies in Europe, North America, and Brazil. (ClinicalTrials.gov number, NCT 
00485732.)
Keywords: AS04-adjuvanted, Cervical cancer, Geometric mean titres, Human papillomavirus-16/18, Immunogenicity, 
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INTRODUCTION
Cervical cancer is the second most common form of cancer 
in women worldwide, with approximately 555,100 new cases 
and 309,800 deaths reported in 2007; 83% of these cervical 
cancer deaths occur in developing countries [1]. The pattern 
of cervical cancer incidence and mortality in Korea is similar to 
that seen in a developing country setting [2]. 
In Korea, cervical cancer is the fifth most common malignant 
cancer reported with over 3,000 women developing this 
disease annually [3], and accounting for 9.8% of new cancer 
cases in Korean women [4]. The age-standardised rate (ASR) 
for cervical cancer has shown a decline from 19 per 100,000 
women in 1993-1995 to 15 per 100,000 women in 1999-2002 
in Korea [2]. According to Cancer Incidence in Five Continents 
(Volume IX), the ASR for cervical cancer in Korea has shown to 
be intermediate at 15.4 per 100,000 women [5].
Amongst the various risk factors associated with cervical 
cancer [6], persistent infection with oncogenic human 
papillomavirus (HPV) types is established as an essential 
precursor to the development of cervical cancer [7,8]. Of 
the 15 oncogenic HPV types identified, HPV-16 and HPV-
18 together account for approximately 70% of all invasive 
cervical cancer (ICC) cases worldwide, with HPV-45, -33, and 
-31 accounting for additional approximately 10% of reported 
cases [9]. In Korea, HPV-16, -18, -58, -33, and -52 accounts for 
80.8% of all ICC cases, while 65.1% of ICC are caused by HPV-
16 and -18 alone. The prevalence of HPV-58, -33, and -52 is 
high in high-grade cervical intraepithelial neoplasia (CIN) and 
invasive cancer in Korean women when compared to many 
other countries [10]. 
The World Health Organisation (WHO) has recognised cervical 
cancer and other HPV-related diseases as a global public health 
problem and recommends the inclusion of routine HPV vacci-
nation in national immunisation programmes worldwide 
[11]. The HPV-16/18 AS04-adjuvanted cervical cancer vaccine 
(Cervarix
Ⓡ, GlaxoSmithKline [GSK] Biologicals, Rixensart, Belgi-
um) has been developed and licensed in more than 100 coun-
tries worldwide, including US, Europe, Japan, and Korea. In 
addi  tion, a pre-qualification has been awarded to Cervarix
Ⓡ 
by the WHO to ensure access of the vaccine and help combat 
cervical cancer in developing countries [12]. The vaccine has 
been shown to be immunogenic and having a clinically 
acceptable safety profile in global clinical studies [13-18], 
and high efficacy against persistent HPV-16/18 infection and 
CIN2+ up to 6.4 years after vaccination [13,19]. 
Over 58,000 girls and women are currently enrolled in/
have participated in clinical trials for the HPV-16/18 AS04-
adjuvanted cervical cancer vaccine. The vaccine is already in 
use as part of routine immunisation programmes in countries 
such as the Netherlands and the UK to protect women against 
cervical cancer [20,21]. 
This phase IIIB study was conducted in healthy Korean 
women aged 15-25 years to evaluate the immunogenicity, 
safety and reactogenicity of the vaccine. 
MATERIALS AND METHODS
　　
1. Study design and participants
Healthy Korean women aged 15-25 years at the time of first 
vaccination were recruited for this phase IIIB, double-blind, 
placebo-controlled, multi-centre trial conducted from June 
2007 to March 2008 in six Korean centres (Study ID:107291). 
Women were ran  do  mised (2:1, vaccine:placebo) to receive 
three doses of either the HPV-16/18 AS04-adjuvanted vaccine 
(HPV group), or Al(OH)3 placebo (ALU group); administered 
intramuscularly according to a 0, 1, and 6 months schedule. 
Study participants were to have a negative urine pregnancy 
test before each vaccination and agree to use adequate con-
tra  ceptive precautions over the vaccination period. Women 
were excluded from participating in the study if they had 
used any investigational or non-regi  stered drug or vaccine, 
were pregnant or lactating or plan  ning/ likely to conceive du-
ring the study. Additionally, subjects with a history of HPV 
vaccination, monophosphoryl lipid A (MPL) or AS04-adjuvant 
administration, and those with a history of chronic diseases 
such as autoimmune diseases or cancer were also excluded 
from study participation.
The study was conducted in accordance with Good Clinical 
Practice guidelines and adhered to all applicable regulatory 
re  quirements, including the Declaration of Helsinki. The study pro-
tocol and informed consent documentation were approved 
by the Independent Ethics Committee or Institutional Review 
Board of each study centre. All participants and/or parents/
guardians of the participants provided written informed con-




Each dose of the HPV-16/18 vaccine contained 20 mg each of 
HPV-16 and -18 L1 (structural protein of HPV) virus like particle 
and adjuvanted with the proprietary immunostimulatory AS04 
adjuvant system (comprising 3-O desacyl-4’-MPL [50 mg] ad-
sorbed on aluminium hydroxide [Al(OH)3, 500 mg]) [18]. The 
placebo contained 500 mg of aluminium as Al(OH)3 without 
any viral antigen. 
The HPV-16/18 AS04-adjuvanted cervical cancer vaccine was HPV-16/18 AS04-adjuvanted vaccine: phase IIIB trial in Korea
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developed and manufactured by GSK Biologicals, Belgium. The 
vaccine was supplied in 0.5 mL pre-filled individual syringes.
　　
3. Randomisation sequence and treatment allocation
The randomisation of the study vaccine/placebo was 
performed at GSK Biologicals, using a standard statistical 
analysis system programme. Random allocation of participants 
was done with a 2:1 blocking scheme using an internet based 
randomisation system (SBIR) at the investigator site. The 
randomisation algorithm used a minimisation procedure. 
The blocking system was used to ascertain that balance was 
maintained between the treatment arms. A single treatment 
number was utilised in the entire study to identify the vaccine 
doses to be administered to the participant. 
All participants and study personnel directly involved in the 
study conduct were blinded throughout the study until the 
last subject and last visit and the database was frozen.
4. Immunogenicity assessment
Blood samples (5 mL) were collected before vaccination and 
one month post-dose 3 to evaluate the antibody response 
against HPV-16 and HPV-18 using ELISA [22]. The assay cut-
off for anti-HPV-16 and anti-HPV-18 antibodies was ≥8 ELISA 
units/millilitre (EL.U/mL) and ≥7 EL.U/mL, respectively [23].
 5. Reactogenicity and safety assessment
Diary cards were given to participants or parents/guardians of 
the participants on the day of vaccination to record solicited 
and unsolicited (local/general) symptoms during the 7-day 
and 30-day post-vaccination follow-up period, respectively. 
Solicited local symptoms (pain, redness and swelling at 
the injection site) and solicited general symptoms (fever, 
headache, fatigue, gastrointestinal symptoms, myalgia, 
arthralgia, rash, and urticaria) were recorded during the 
7-day follow-up period after each vaccine/placebo dose. 
The intensity of solicited symptoms was graded on a scale 
of 0-3 based on the extent of discomfort experienced by the 
participants. Grade 3 (severe) symptoms were defined as: 
pain that prevented normal day-to-day activity, redness or 
swelling with an injection site diameter greater than 50 mm, 
temperature higher than 39
oC as fever, urticaria distributed 
on at least four body areas, or an adverse event (AE) that 
prevented normal activities. Post-vaccination reactions 
(urticaria or rash that appeared within 30 minutes of each 
vaccine dose) were also documented immediately by the 
investigator. Each solicited AEs and unsolicited AEs were 
tabulated with exact 95% confidence intervals (CIs) for all 
vaccine doses and overall.
Serious adverse events (SAEs), new onset chronic diseases 
(NOCDs) such as autoimmune diseases, asthma, type I 
diabetes and allergies, other medically significant conditions 
(MSCs) and pregnancy/pregnancy outcomes were recorded 
throughout the study period. An event was considered to be 
an NOCD if it had not been recorded in the previous medical 
history of the participants’ vaccination (i.e., new onset); 
MSCs were defined as prompting an emergency room, or 
a physician visit that is unrelated to common diseases or 
routine visits for physical examination or vaccination, or SAEs 
unrelated to common diseases.
 
6. Statistical analysis
Primary analysis of immunogenicity was performed on 
the according-to-protocol (ATP) cohort, which included 
all evaluable participants (those meeting all eligibility 
criteria, complying with protocol defined procedures, 
without elimination criteria during the study) for whom 
immunogenicity data were available. The primary analysis of 
safety was done on the total vaccinated cohort that included 
all participants with at least one vaccine/placebo dose 
administered.
A sample size of 120 evaluable participants in the HPV group 
was required to demonstrate, with at least 92% power, that 
seroconversion rates for HPV-16 and -18 one month post-dose 
3 were not less than 90%. The power calculation was based 
on a one-sided exact test for one binomial population, type 
I error of 2.5% with the Bonferroni adjustment of beta using 
PASS2005 (NCSS, Kaysville, UT, USA).
Seroconversion/seropositivity rates for anti-HPV-16 and 
anti-HPV-18 antibodies were calculated with their 95% CI. 
Seroconversion was defined as the appearance of antibodies 
(i.e., titre ≥cut-off value) in the serum of subjects who are 
seronegative before vaccination. A seropositive subject was 
one whose serum antibody titres were ≥cut-off value prior to 
vaccination. Geometric mean titres (GMTs) with 95% CI and 
antibody titres range were also tabulated. GMT calculations 
were performed by taking the anti-log of the mean of the log 
antibody titres transformations. Antibody titres below the 
assay cut-off were given an arbitrary value of half the cut-off 
for GMT calculation.
All statistical analysis was performed using SAS ver. 9.1 (SAS 
Inc., Cary, NC, USA) programme and Proc StatXact ver. 7.0 (Cytel 




The study groups are outlined in (Fig. 1). A total of 225 women Seung Cheol Kim, et al.
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Table 1. Baseline serological status (ELISA) (total vaccinated cohort)
HPV-16  HPV-18 HPV group (N=149) ALU group (N=76) ALL (N=225)
Seropositive Seropositive 3 (2.1) 1 (1.3) 4 (1.8)
Seropositive Seronegative 8 (5.5) 5 (6.6) 13 (5.9)
Seronegative Seropositive 10 (6.8) 7 (9.2) 17 (7.7)
Seronegative Seronegative 125 (85.6) 63 (82.9) 188 (84.7)
Serology not available for at least one vaccine antigen 3 (-) 0 (-) 3 (-)
HPV group, subjects who received the HPV-16/18 L1 VLP AS04-adjuvanted vaccine; ALU group, subjects who received Al(OH)3; N, number of 
subjects in each group; n (%), number/percentage of subjects in the considered category.
Fig. 1. Study participants flowchart. N, total number of subjects; n, number of subjects with elimination code assigned excluding ones who 
have been assigned a lower elimination code number.HPV-16/18 AS04-adjuvanted vaccine: phase IIIB trial in Korea
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were enrolled of whom 208 completed the study (141 in the 
HPV group and 67 in the ALU group). The ATP safety cohort 
consisted of 208 women (140 in the HPV group and 68 in the 
ALU group). The ATP cohort for immunogenicity included 
204 women (137 in the HPV group and 67 in the ALU group) 
(Fig. 1). The mean age of women was 22±2.37 years (total 
vaccinated cohort). All of them were Asian with East Asian He-
ritage.
 2. Immunogenicity
Seropositivity status at baseline was similar in the two groups. 
Of the women in the total vaccinated cohort, 85.6% in the 
HPV group and 82.9% in the ALU group were seronegative for 
both HPV-16 and -18 antibodies before vaccination (Table 1).
In the ATP immunogenicity cohort, initially seronegative 
women in the HPV-16/18 group showed 100% seroconversion 
for anti-HPV-16 and anti-HPV-18 antibodies at one month 
Table 3. Immune response to HPV-18 (according-to-protocol cohort for immunogenicity)
Group Pre-vaccination status Timing No. ≥7 EL.U/mL
% (95% CI)
GMT (95% CI)
HPV  Seronegative  Pre-vaccination 122 0 (0.0-3.0) 3.5 (3.5-3.5)
One month post-dose 3 122 100 (97.0-100) 4,204.1 (3,626.5-4,873.6)
Seropositive  Pre-vaccination 13 100 (75.3-100) 16.3 (9.5-27.8)
One month post-dose 3 13 100 (75.3-100) 4,595.0 (2,970.2-7,108.5)
Total Pre-vaccination 135 9.6 (5.2-15.9) 4.1 (3.7-4.4)
One month post-dose 3 135 100 (97.3-100) 4,240.2 (3,692.1-4,869.7)
ALU Seronegative Pre-vaccination 61 0 (0.0-5.9) 3.5 (3.5-3.5)
One month post-dose 3 60 5.0 (1.0-13.9) 3.8 (3.4-4.3)
Seropositive Pre-vaccination 6 100 (54.1-100) 15.6 (5.6-43.1)
One month post-dose 3 6 83.3 (35.9-99.6) 14.1 (5.1-38.6)
Total Pre-vaccination 67 9.0 (3.4-18.5) 4 (3.5-4.5)
One month post-dose 3 66 12.1 (5.4-22.5) 4.3 (3.7-5.0)
HPV, subjects who received the HPV-16/18 L1 VLP AS04-adjuvanted vaccine; ALU, subjects who received Al(OH)3; Seronegative, subjects with 
antibody titre <7 ELISA unit (EL.U)/mL prior to vaccination; Seropositive, subjects with antibody titre ≥7 EL.U/mL prior to vaccination; N, number 
of subjects with pre-vaccination results available in each group; % (95%CI), percentage of subjects with concentration ≥ specified cut-off with 
exact 95% confidence interval.
Table 2. Immune response to HPV-16 (according-to-protocol cohort for immunogenicity)
Group Pre-vaccination status Timing No.
≥8 EL.U/mL
% (95% CI) GMT (95% CI)
HPV Seronegative Pre-vaccination 125 0 (0.0-2.9) 4 (4.0-4.0)
One month post-dose 3 125 100 (97.1-100) 9,351.4 (8,145.5-1,0735.8)
Seropositive Pre-vaccination 11 100 (71.5-100) 23 (12.2-43.3)
One month post-dose 3 11 100 (71.5-100) 7,918.1 (4,683.5-13,386.7)
Total Pre-vaccination 136 8.1 (4.1-14.0) 4.6 (4.2-5.1)
One month post-dose 3 136 100 (97.3-100) 9,226.4 (8,085.4-10,528.4)
ALU Seronegative Pre-vaccination 61 0 (0.0-5.9) 4 (4.0-4.0)
One month post-dose 3 61 3.3 (0.4-11.3) 4.1 (3.9-4.3)
Seropositive Pre-vaccination 6 100 (54.1-100) 33.2 (14.9-73.8)
One month post-dose 3 6 83.3 (35.9-99.6) 28.8 (9.2-89.6)
Total Pre-vaccination 67 9.0 (3.4-18.5) 4.8 (4.1-5.7)
One month post-dose 3 67 10.4 (4.3-20.3) 4.9 (4.2-5.8)
HPV, subjects who received the HPV-16/18 L1 VLP AS04-adjuvanted vaccine; ALU, subjects who received Al(OH)3; Seronegative, subjects with 
antibody titre <8 ELISA unit (EL.U)/mL prior to vaccination; Seropositive, subjects with antibody titre ≥8 EL.U/mL prior to vaccination; N, number 
of subjects with pre-vaccination results available in each group; % (95%CI), percentage of subjects with concentration ≥ specified cut-off with 
exact 95% confidence interval.Seung Cheol Kim, et al.
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post-dose 3. All initially seropositive women remained 
seropositive for HPV-16 and/or HPV-18 antibodies one month 
post-dose 3 in the HPV group (Tables 2 and 3).
GMTs in the HPV group in the initially seronegative and 
seropositive women were 9,351.4 El.U/mL (95% CI, 8,145.5 to 
10,735.8) and 7,918.1 El.U/mL (95% CI, 4,683.5 to 13,386.7) for 
anti-HPV-16 antibodies and 4,204.1 El.U/mL (95% CI, 3,626.5 
to 4,873.6) and 4,595.0 El.U/mL (95% CI, 2,970.2 to 7,108.5) for 
anti-HPV-18 antibodies, respectively, one month post-dose 3. 
GMTs for initially seronegative and seropositive women in the 
ALU group are shown in (Tables 2 and 3).
3. Safety and reactogenicity (total vaccinated cohort)
The compliance rate with respect to returning the diary 
cards were similar in the HPV group (98.4%) and the ALU 
group (97.2%). 
1) Solicited local and general AEs
Solicited local symptoms were reported more frequently in the 
HPV group than the ALU group. Pain at the injection site was 
the most frequently reported local symptom in both groups 
(Fig. 2). Grade 3 symptoms were rarely reported in both groups 
(pain reported after 4.4% of doses in the HPV group, redness 
and swelling after 0.9% and 1.2% of doses in the HPV group). 
In the ALU group, grade 3 symptoms were reported following 
≤0.5% of doses. Most of these local symptoms were transient 
with a mean duration of 3.4-3.7 days for each symptom in the 
HPV group and 2.3-2.4 days in the ALU group.
During the 7-day post-vaccination follow-up period, the 
occurrence of fatigue, myalgia and headache was frequent in 
both groups. Fatigue, myalgia and gastrointestinal symptoms 
were recorded more frequently in the HPV group than the ALU 
group (overall/dose) (Fig. 3). Grade 3 symptoms reported were 
generally low across both groups (not exceeding 2.8% of doses 
in the HPV group). In the ALU group, grade 3 symptoms were 
not reported except for headache (after 1.4% of doses) and my-
algia (after 1.0% of doses) (Fig. 3). The mean duration of soli-
cited general symptoms was 2.1-3.0 days in the HPV group, 
lasting longer for arthralgia, myalgia, rash and urticaria. In the 
ALU group, the mean duration was 1.0-2.6 days. None of the 
subjects reported urticaria or rash in the 30-minute post-vacci-
nation period in both groups.
Compliance to the 3-dose vaccination course was high 
(95.3% of women in the HPV group [n=142] and 89.5% of 
women in the ALU group [n=68] [total vaccinated cohort]).
2) Unsolicited adverse events, MSCs, NOCDs, SAEs, and pre­
gnancy
Unsolicited AEs were reported after 20.4% (95% CI, 16.7 to 
24.5) of doses in the HPV group (number of administered 
doses, 436) and after 10.2% (95% CI, 6.5 to 15.0) of doses in the 
ALU group (number of administered doses, 216). Infections 
and infestations (after 6.9% of doses in the HPV group and 
3.2% of doses in the ALU group overall) followed by breast 
and reproductive system disorders (after 3.7% of doses in 
the HPV group and 1.4% of doses in the ALU group overall) 
were the most frequently reported symptoms in both groups. 
No imbalance in the incidence of any individual unsolicited 
symptoms was identified between the two groups. Grade 
3 unsolicited AEs were reported after 0.9% of doses in the 
HPV group (gastrointestinal disorder, vomiting, pain, upper 
respiratory tract infection, and dizziness), and after 0.5% of 
doses in the ALU group (injection site warmth and malaise). 
At least one medically significant adverse condition was 
Fig. 2. Solicited local symptoms (overall/dose) with 95% confidence 
interval during the 7-day post-vaccination period (total vaccinated 
cohort). HPV group: N=429, ALU group: N=210.
Fig. 3. Solicited general symptoms reported overall/dose during the 
7-day post-vaccination period (total vaccinated cohort). HPV group: 
N=429, ALU group: N=210.HPV-16/18 AS04-adjuvanted vaccine: phase IIIB trial in Korea
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reported by 22.8% of women in the HPV group and 13.2% of 
women in the ALU group. Gastrointestinal disorders and skin 
and subcutaneous tissue disorders were the most commonly 
reported in both groups. Eleven women (five [3.4%] in the 
HPV group and six [7.9%] in the ALU group) reported at 
least one NOCD in the study (GSK assessment based on pre-
defined list).
Three non-fatal SAEs (gastroenteritis viral, pelvic inflam-
matory disease, and ruptured ovarian cyst) were reported 
during the study (two in the HPV group and one in the ALU 
group). The investigator did not consider these to be related 
to vaccination and they all recovered. One pregnancy was 
reported in the ALU group during the study. This woman 
opted for elective abortion after 12 weeks of pregnancy due 




Despite regular cytology screening becoming an effective 
tool in cervical cancer prevention, cervical cancer continues 
to pose a considerable threat in the developing parts of the 
world [24,25]. Although Korea is no longer a developing 
country, the incidence and mortality rate of cervical cancer 
in Korea suggests that cervical cancer is still a major health 
concern in the region [2,3]. Two studies which included 
Korean adolescents aged 10-14 years have been conducted 
previously to evaluate the immunogenicity and safety of the 
HPV-16/18 AS04-adjuvanted vaccine [26,27]. The present 
study was conducted in Korean girls 15-25 years of age.
In the present study, all women initially seronegative for 
anti-HPV-16 and -18 antibodies seroconverted at one month 
post-dose 3, with high antibody titres achieved against both 
antigens. Initially seropositive women exhibited comparable 
GMTs one month post-dose 3 as in the initially seronegative 
women. The GMT levels in the current study were at least 
180 fold higher for both antigens one month post-dose 3 
than those observed after natural infection with HPV-16/18 
[16]. The level of protection conferred and the immunity 
induced following a natural infection are unknown. However, 
it is shown that not all women develop serum antibodies to 
HPV after a natural infection [28], and because antibodies 
after a natural infection are relatively low and do not reliably 
protect against re-infection, women who may have already 
been exposed to the infection are still susceptible to re-
infection. Vaccination with the HPV-16/18 AS04-adjuvanted 
cervical cancer vaccine helps in inducing sustained antibody 
responses. The high immunogenicity, the role of novel AS04-
adjuvant in the induction of high immune response and its 
implications have been shown and elaborated in a previous 
study in Korean pre-teens and young adolescents aged 10-14 
years [27]. Immunological superiority of the AS04-adjuvanted 
formulation has been observed before when compared to the 
same antigens adjuvanted with aluminium alone [29,30]. 
Although the current study did not evaluate the efficacy of 
the vaccine, in a large international phase III study across 14 
countries in women from 15-25 years of age (same age range 
as this study) [13,16], the HPV-16/18 AS04-adjuvanted vaccine 
has demonstrated to be highly efficacious against infections 
and CIN2+ lesions associated with HPV-16 and HPV-18, with 
additional cross-protection against persistent infections and 
cervical lesions with other oncogenic non-vaccine types 
(i.e., HPV -31, HPV-33, and HPV-45). Magnitude of immune 
response (GMTs) achieved in this study was similar to that 
observed in the above global trial, and comparable to other 
HPV trials in women in Asia, Europe and North America, which 
indicates no ethnic differences, and similar efficacy can be 
expected in Korean women 15-25 years of age. 
Although the study was not powered for safety evaluation, 
safety data generated in this study are similar to those shown 
in other global studies [13-17]. Incidence of local injection site 
symptoms and some general symptoms was observed to be 
higher in the HPV group than in the ALU group, with grade 
3 local and general symptoms being rare in both groups. 
The majority of AEs were generally mild and resolved within 
a couple of days, and compliance with vaccinations was 
high with over 90% women completing the full vaccination 
schedule. This is in line with the clinical experience with AS04-
adjuvanted formulations confirming the HPV-16/18 AS04-
adjuvanted vaccine to have a clinically acceptable safety 
profile in Korean women. 
A rapid change is being observed in the sexual behaviour 
and social activity in Korea, with sexual debut becoming 
earlier in Korean women. This change has led to an increased 
risk of HPV infection in Korean women, which in turn has 
increased the incidence of cervical cancer in this region, as 
confirmed by two surveys conducted in Busan, Korea [31,32]. 
Cervical cancer screening using the Papanicolaou test has 
helped in a considerable reduction in cervical cancer burden 
in Korea since its introduction in the 1950s in the region by 
the Korean Government [2,25]. Regular screening has shown 
to reduce the ICC incidence in a prospective cohort study in 
Korea [33]. However, participation of women in such screening 
programmes is shown to be marked by socioeconomic 
inequality, largely dependent on the socioeconomic status 
of women [34]. Hence, immunisation of adolescents and 
young women before sexual debut can help in providing 
early protection as depicted in a previous study of Korean Seung Cheol Kim, et al.
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population of 10-14 years of age [27], to complement the 
cervical cancer screening programme. Additional measures 
of increased disease awareness amongst young women and 
about the risks and benefits of vaccination and age-based 
interventions policy programmes can further facilitate to 
control the cervical cancer burden in Korea [2,25]. 
In conclusion, the HPV-16/18 AS04-adjuvanted cervical cancer 
vaccine was shown to be highly immunogenic and has a cli  ni-
cally acceptable safety profile in the Korean population of 15-
25 year olds, as previously shown in a Korean population of 10-
14 year old adolescents and girls in another study. With cervical 
cancer being a major health problem in Korean women, pro-
phylactic HPV vaccination may be integrated into routine immu-
nisation programmes, in line with recommendations by the 
WHO, to help combat the cervical cancer disease burden. 
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